PBM Competition in Pharmaceutical Supply Chain: Formulary Design and Drug Pricing

Published Online:https://doi.org/10.1287/msom.2015.0542

References

  • Ali ÖG, Mantrala M (2010) Pharma rebates, pharmacy benefit managers and employer outcomes. Health Care Management Sci. 13(4):281–293.CrossrefGoogle Scholar
  • Anderson SP, De Palma A (1992) Multiproduct firms: A nested logit approach. J. Indust. Econom. 40(3):261–276.CrossrefGoogle Scholar
  • Bhatia T, Hansen K, Krishnamurthi L (2006) Modeling key drivers of physician’s choice of prescription drugs: An integrated view incorporating patient and physician heterogeneity. Working paper, Kellogg School of Management, Northwestern University, Evanston, IL.Google Scholar
  • Carrera M (2010) The role of patient co-payments in prescribing and refill decisions. Working paper, University of California, Berkeley, Berkeley.Google Scholar
  • Centers for Medicare and Medicaid Services (2012) National health expenditures; aggregate and per capita amounts, annual percent change and percent distribution, by type of expenditure: Selected calendar years 1960–2012. Last accessed December 16, 2014, http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/tables.pdf.Google Scholar
  • Claxton G, Rae M, Panchal N, Lundy J, Damico A, Osei-Anto A, Kenward K, Whitmore H, Pickreign J (2011) Employer Health Benefits: 2011 Annual Survey (Henry J. Kaiser Family Foundation, Menlo Park, CA, and Health Research & Educational Trust, Chicago).Google Scholar
  • Cui H, Desai P, Wang H (2014) Pharmaceutical distribution through PBMs: Market shares, bargaining power and insurance plan heterogeneity. Working paper, Carlson School of Management, University of Minnesota, Minneapolis.Google Scholar
  • Deneckere R, Davidson C (1985) Incentives to form coalitions with Bertrand competition. RAND J. Econom. 16(4):473–486.CrossrefGoogle Scholar
  • Epstein AJ, Ketcham JD (2010) Influencing physicians’ prescribing decisions through detailing, samples, prior authorizations, and patient copays. Working paper, Arizona State University, Tempe.Google Scholar
  • Esposito D (1995) Copayments and the Demand for Prescription Drugs, 1st ed. (Routledge, New York).Google Scholar
  • Federgruen A, Pierson M (2011) The impact of horizontal mergers and acquisitions in price competition models. Working paper, Columbia Business School, New York.CrossrefGoogle Scholar
  • Gallego G, Huh WT, Kang W, Phillips R (2006) Price competition with the attraction demand model: Existence of unique equilibrium and its stability. Manufacturing Service Oper. Management 8(4):359–375.LinkGoogle Scholar
  • Garis RI, Clark BE (2004) The spread: Pilot study of an undocumented source of pharmacy benefit manager revenue. J. Amer. Pharmacists Assoc. 44(1):15–21.CrossrefGoogle Scholar
  • Goldman DP, Joyce GF, Zheng Y (2007) Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. J. Amer. Medical Assoc. 298(1):61–69.CrossrefGoogle Scholar
  • Grabowski HG, Mullins CD (1997) Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc. Sci. Medicine 45(4):535–544.CrossrefGoogle Scholar
  • Henry J. Kaiser Family Foundation (2005) Follow the pill: Understanding the U.S. commercial pharmaceutical supply chain. Last accessed December 16, 2014, http://kff.org/other/report/follow-the-pill-understanding-the-u-s/.Google Scholar
  • Hoadley J, Hargrave E, Merrell K (2011) Medicare Part D formularies, 2006–2011: Update to chartbook. Report, MedPAC, Washington, DC. Last accessed December 16, 2014, http://www.medpac.gov/documents/contractor-reports/Aug11_PartDFormulariesChartbook_Updated_CONTRACTOR_ss.pdf.Google Scholar
  • Lang SL (2013) Interview on current practice in PBM industry. Date of interviews: August 16, 2012 and July 20, 2013. https://www.linkedin.com/in/susanllang.Google Scholar
  • Li H, Huh WT (2011) Pricing multiple products with the multinomial logit and nested logit models: Concavity and implications. Manufacturing Service Oper. Management 13(4):549–563.LinkGoogle Scholar
  • Lipton HL, Kreling DH, Collins T, Herts KC (1999) Pharmacy benefit management companies: Dimensions of performance. Annual Rev. Public Health 20:361–401.CrossrefGoogle Scholar
  • Navarro RP (2009) Managed Care Pharmacy Practice, 2nd ed. (Jones and Bartlett Publishers, Sudbury, MA).Google Scholar
  • Olson BM (2003) Approaches to pharmacy benefit management and the impact of consumer cost sharing. Clinical Therapeutics 25(1):250–272.CrossrefGoogle Scholar
  • Pharmacy Benefit Management Institute (2014) Top 10 pharmacy benefit management companies and market share by annual prescription volume, as of 2nd quarter 2011. Last accessed December 16, 2014, http://pbmi-com.web33.winsvr.net/PBMmarketshare2.asp.Google Scholar
  • Rentmeester CA, Garis RI (2008) Rebates and spreads: Pharmacy benefit management practices and corporate citizenship. J. Health Politics, Policy and Law 33(5):943–963.CrossrefGoogle Scholar
  • Rizzo JA, Zeckhauser R (2009) Generic script share and the price of brand-name drugs: The role of consumer choice. Internat. J. Health Care Finance Econom. 9(3):291–316.CrossrefGoogle Scholar
  • Shelanski HA, Farrell J, Hanner D, Metcalf CJ, Sullivan MW, Wendling BW (2012) Economics at the FTC: Drug and PBM mergers and drip pricing. Rev. Indust. Organ. 41(4):303–319.CrossrefGoogle Scholar
  • Small K, Rosen H (1981) Applied welfare economics with discrete choice models. Econometrica 49(1):105–130.CrossrefGoogle Scholar
  • Topkis DM (1998) Supermodularity and Complementarity (Princeton University Press, Princeton, NJ).CrossrefGoogle Scholar
  • Train K (2003) Discrete Choice Methods with Simulation, 1st ed. (Cambridge University Press, Cambridge, UK).CrossrefGoogle Scholar
  • Werden GJ, Froeb LM (1994) The effects of mergers in differentiated products industries: Logit demand and merger policy. J. Law, Econom., Organ. 10(2):407–426.Google Scholar
  • Williams H (1977) On the formation of travel demand models and economic evaluation measures of user benefit. Environment and Planning A 9(3):285–344.CrossrefGoogle Scholar
INFORMS site uses cookies to store information on your computer. Some are essential to make our site work; Others help us improve the user experience. By using this site, you consent to the placement of these cookies. Please read our Privacy Statement to learn more.